The stock of Sarepta Therapeutics Inc (SRPT) has seen a -9.39% decrease in the past week, with a -13.35% drop in the past month, and a -18.25% decrease in the past quarter. The volatility ratio for the week is 4.15%, and the volatility levels for the past 30 days are at 3.58% for SRPT. The simple moving average for the last 20 days is -12.19% for SRPT stock, with a simple moving average of -16.40% for the last 200 days.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
The price-to-earnings ratio for Sarepta Therapeutics Inc (NASDAQ: SRPT) is above average at 90.64x, Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SRPT is 89.66M, and currently, short sellers hold a 6.24% ratio of that floaft. The average trading volume of SRPT on November 15, 2024 was 841.85K shares.
SRPT) stock’s latest price update
Sarepta Therapeutics Inc (NASDAQ: SRPT) has seen a decline in its stock price by -3.00 in relation to its previous close of 112.48. However, the company has experienced a -9.39% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-08 that Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025 and a potential BLA filing by mid-2025. Despite strong revenues, Sarepta may need to raise additional funds within the next 12 months to support ongoing operations and development programs from its pipeline.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Cantor Fitzgerald repeating the rating for SRPT by listing it as a “Overweight.” The predicted price for SRPT in the upcoming period, according to Cantor Fitzgerald is $167 based on the research report published on November 07, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $165. The rating they have provided for SRPT stocks is “Buy” according to the report published on October 21st, 2024.
Raymond James gave a rating of “Outperform” to SRPT, setting the target price at $150 in the report published on October 10th of the current year.
SRPT Trading at -12.15% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.02% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 4.15%, as shares sank -12.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.43% lower at present.
During the last 5 trading sessions, SRPT fell by -9.39%, which changed the moving average for the period of 200-days by -8.30% in comparison to the 20-day moving average, which settled at $124.26. In addition, Sarepta Therapeutics Inc saw 13.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Estepan Ian Michael, who sale 5,985 shares at the price of $137.36 back on Aug 30 ’24. After this action, Estepan Ian Michael now owns 33,946 shares of Sarepta Therapeutics Inc, valued at $822,100 using the latest closing price.
Estepan Ian Michael, the Officer of Sarepta Therapeutics Inc, proposed sale 5,985 shares at $137.37 during a trade that took place back on Aug 30 ’24, which means that Estepan Ian Michael is holding shares at $822,130 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.85 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.07. The total capital return value is set at 0.03. Equity return is now at value 12.27, with 3.63 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 5.69.
Currently, EBITDA for the company is -439.2 million with net debt to EBITDA at 7.82. When we switch over and look at the enterprise to sales, we see a ratio of 7.09. The receivables turnover for the company is 3.78for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.84.
Conclusion
In a nutshell, Sarepta Therapeutics Inc (SRPT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
